Shaping the Future of Toxicology:
Discover VICT3R!
The VICT3R project (Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research) is a public-private partnership funded by the European Innovative Health Initiative (IHI), dedicated to reducing animal use in toxicology research. Aligned with the 3Rs principles—Replacement, Reduction, and Refinement—VICT3R aims to revolutionize the field by developing innovative Virtual Control Groups (VCGs) that not only enhance scientific outcomes but also uphold higher ethical standards. Running from 1st of September 2024 to 29th of February 2028, the project is set to make a significant impact in toxicology research.
Transformative Impact
VICT3R aims to revolutionize toxicology studies by replacing up to 25% of animals used in experiments with Virtual Control Groups (VCGs), setting new standards for ethical research.
Innovative Solutions
By leveraging decades of historical control data combined with cutting-edge AI and advanced statistical methods, we will develop, validate, and implement VCGs for a more humane and efficient approach.
Collaborative Efforts
With 33 partners, including industry leaders, innovative SMEs, and top academic institutions, VICT3R unites the best minds to advance the VCG concept.
Data Excellence
We are building a comprehensive, high-quality database of control animal data, accessible to researchers, regulators, and policymakers worldwide, driving better science and transparency.
Regulatory Acceptance
VICT3R is dedicated to achieving scientific and regulatory validation of VCGs, paving the way for their widespread adoption in toxicology research.
Why VICT3R Matters
Funding and Support
VICT3R is supported by €28 million in funding from the Innovative Health Initiative Joint Undertaking (IHI JU), along with contributions from industry partners. This substantial backing enables VICT3R to drive innovation and achieve its ambitious goals in reducing animal use in toxicology research.
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101172693.
The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe and Instem Scientific Limited.
Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.
Project Partners
VICT3R brings together 33 partner organizations in a powerful alliance led by Pompeu Fabra University (Barcelona, Spain) and Bayer AG (Berlin, Germany). This partnership includes 20 industry leaders, 7 innovative small- and medium-sized enterprises, and 6 top-tier academic institutions. Together, we will drive the development of Virtual Control Groups (VCGs), leveraging decades of control animal data from the pharmaceutical, industrial, and academic sectors.
